(Q41140233)

27 September 2017

Limitations of the Fast Green Assay for Chemosensitivity Testing in Human Lung Cancer (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

22 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1657540

Cardiology and cardiovascular medicine

22 October 2022

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

22 October 2022

5

Postmus PE

1 reference

27 September 2017

2

E. G. de Vries

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1657540

22 October 2022

author name string

de Vries EG

2

1 reference

27 September 2017

E. F. Smit

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1657540

22 October 2022

C. Meijer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1657540

22 October 2022

N. H. Mulder

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1657540

22 October 2022

language of work or name

English

0 references

publication date

1 November 1991

1 reference

full work available at URL

27 September 2017

https://api.elsevier.com/content/article/PII:S0012369216336911?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

https://api.elsevier.com/content/article/PII:S0012369216336911?httpAccept=text/plain

22 October 2022

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

22 October 2022

1 reference

27 September 2017

100

1 reference

27 September 2017

1358-1363

1 reference

27 September 2017

5

1 reference

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

27 September 2017

3

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

22 October 2022

4

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Current status of therapy for small cell carcinoma of the lung

22 October 2022

5

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

22 October 2022

6

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

In vitro chemosensitivity of human lung cancer for vindesine

22 October 2022

7

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

A novel dye exclusion method for testing in vitro chemosensitivity of human tumors

22 October 2022

9

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

In vitro chemosensitivity of human bladder cancer

22 October 2022

10

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

22 October 2022

11

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs

22 October 2022

12

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Send This Patient's Tumor for Culture and Sensitivity

22 October 2022

13

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

22 October 2022

14

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial

22 October 2022

15

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer

22 October 2022

16

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue.

22 October 2022

17

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

The human tumor cloning assay in cancer research and therapy: a review with clinical correlations

22 October 2022

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Predicting response of human solid tumors to chemotherapy

22 October 2022

19

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Clinical relevance of predictive tests for cancer chemotherapy

22 October 2022

21

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Limitations of the clonal agar assay for the assessment of primary human ovarian tumour biopsies.

22 October 2022

25

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Tumor Cell Lines Established in Vitro: An Independent Prognostic Factor for Survival in Non-Small-Cell Lung Cancer

22 October 2022

26

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Lack of relationship between in vitro tumor cell growth and prognosis in extensive-stage small-cell lung cancer

22 October 2022

27

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy

22 October 2022

29

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Activity of 9–10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system

22 October 2022

30

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Evaluation of new anthracycline analogs with the human tumor stem cell assay

22 October 2022

31

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Human tumor cloning: feasibility and clinical correlations

22 October 2022

33

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial

22 October 2022

35

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features

22 October 2022

36

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer

22 October 2022

37

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining

22 October 2022

39

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Expression of a multidrug resistance gene in human cancers

22 October 2022

40

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction

22 October 2022

41

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia.

22 October 2022

43

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

Predictive chemosensitivity testing

22 October 2022

44

1 reference

https://api.crossref.org/works/10.1378/CHEST.100.5.1358

22 October 2022

Identifiers

1 reference

27 September 2017

1 reference